Increase plasma donations by 16% until April and expect to continue growing
BARCELONA, 10 Jun. (EUROPA PRESS) –
Grifols plans to reduce its investments in capex over the next two years, not to carry out “significant corporate operations” and save on structural costs with the aim of reducing its net financial debt to Ebitda ratio to below 4 times in 2023 and 3, 5 times in 2024.
In a statement this Friday after the company’s general shareholders’ meeting, Grifols explained that plasma donations have accelerated in 2022 and that until April they had increased by 16% year-on-year and that “volumes of plasma are expected to continue to increase”. plasma during fiscal year 2022″.
The main items on the agenda submitted for vote have been approved by the shareholders, including the annual accounts and the management reports, as well as the appointments of Montserrat Muñoz Abellana and Susana González Rodríguez as independent directors.
The co-ceo of the company Víctor Grifols Deu has highlighted that the purchase of Biotest -closed in September 2021– will allow it to enhance its portfolio of R & D projects; expand and diversify the supply of plasma and the availability of therapies, and favor the economic performance of the company.
The operation has allowed Grifols to have a network of 403 plasma centers around the world and to focus “its efforts on speeding up the ongoing clinical trials of two new proteins not currently used: Trimodulin (IgM) and fibrinogen”.
Co-CEO Raimon Grifols Roura highlighted the company’s business model, based on the conviction that the evolution of financial results must be compatible with a project that is sustainable and profitable in the long term, also from a social and economic point of view. environmental.
He recalled that the company promotes a plan of 30 corporate objectives grouped into six pillars and that include 100% of the electricity consumed being renewable, reducing greenhouse gas emissions by 55% and reaching 50% of women in ‘senior management’.
